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OBJECTIVE: This study sought to compare the effects and outcomes of two ophthalmic viscosurgical devices, 1.6%
hyaluronic acid/4.0% chondroitin sulfate and 2.0% hydroxypropylmethylcellulose, during phacoemulsification.
METHODS: This prospective, randomized clinical trial comprised 78 eyes (39 patients) that received phacoemulsifica-
tion performed by the same surgeon using a standardized technique. Patients were randomly assigned to receive
either 1.6% hyaluronic acid/4.0% chondroitin sulfate or 2.0% hydroxypropylmethylcellulose on the first eye. The
other eye was treated later and received the other viscoelastic agent. Preoperative and postoperative examinations
(5, 24 and 48 hours; 7 and 14 days; 3 and 6 months) included measurements of the total volume of the ophthalmic
viscosurgical device, ultrasound and washout times to completely remove the ophthalmic viscosurgical device,
intraocular pressure, central corneal thickness and best-corrected visual acuity. The corneal endothelial cell count
was measured at baseline and at six months postoperatively. ClinicalTrials.gov: NCT01387620.
RESULTS: There were no statistically significant differences between groups in terms of cataract density or
ultrasound time. However, it took longer to remove 2.0% hydroxypropylmethylcellulose than 1.6% hyaluronic acid/
4.0% chondroitin sulfate, and the amount of viscoelastic material used was greater in the 2.0% hydroxypro-
pylmethylcellulose group. In addition, the best-corrected visual acuity was significantly better in the hyaluronic acid/
chondroitin sulfate group, but this preferable outcome was only observed at 24 hours after the operation. There
were no statistically significant differences between the two ophthalmic viscosurgical devices regarding the central
corneal thickness or intraocular pressure measurements at any point in time. The corneal endothelial cell count was
significantly higher in the hyaluronic acid/chondroitin sulfate group.
CONCLUSION: The ophthalmic viscosurgical device consisting of 1.6% hyaluronic acid/4.0% chondroitin sulfate was
more efficient during phacoemulsification and was easier to remove after IOL implantation than 2.0%
hydroxypropylmethylcellulose. In addition, the corneal endothelial cell count was significantly higher following
the use of hyaluronic acid/chondroitin sulfate than with hydroxypropylmethylcellulose, which promoted an
improved level of corneal endothelium protection.
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INTRODUCTION
Ophthalmic viscosurgical devices (OVDs) play an impor-
tant role in modern cataract surgery. They maintain
adequate space, facilitate intraocular lens (IOL) implanta-
tion and surgical maneuvers, and they protect the corneal
endothelium during various stages of cataract surgery (1-3).
Transient corneal edema, however, is a common compli-
cation of cataract surgery that delays visual improvement,
especially in the early postoperative period (4,5).
Many viscoelastic substances are available for cataract
surgery and differ depending on their physical and
chemical properties (6). The OVD 2.0% hydroxypropyl-
methylcellulose (2.0% HPMC) has low zero-shear viscosity
and dispersive characteristics (7). This commonly used OVD
is more likely to be retained in the eye than DisCoVisc but
has the disadvantages of poorly maintained spacing and
occasional difficulties with its removal (8,9).
DisCoVisc (1.6% hyaluronic acid/4.0% chondroitin sul-
fate), which combines the rheological behaviors of highly
viscous and dispersive OVDs, was the first viscous dispersive
viscoelastic to become available. The viscous properties of
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DisCoVisc facilitate space maintenance, while its dispersive
properties impart tissue protection (3,10).
This prospective study was performed to compare the
effects and outcomes of DisCoVisc (Alcon Laboratories, Inc.,
Fort Worth, TX) and 2.0% HPMC (Celoftal, Alcon Labo-
ratories, Inc., Fort Worth, TX) during phacoemulsification.
MATERIALS AND METHODS
This prospective, randomized study with intra-individual
comparisons comprised 78 eyes from 39 patients who
received bilateral phacoemulsification. The Institutional
Review Board approved the study, and all patients provided
informed consent before enrollment. The inclusion criteria
consisted of bilateral age-related cataracts from grades 1 to 3
based on the lens opacities classification system (LOCS III),
and no other ocular pathology or condition and pupil dilation
that was greater than 7.0 mm. The exclusion criteria consisted
of black, brunescent, traumatic or subluxated cataracts;
coexisting corneal endothelial disease (endothelial cell count
,2,000 cells/mm2); glaucoma; uveitis and pseudo-exfolia-
tion. Patients who had undergone previous ocular surgery
were also excluded.
Preoperative and postoperative examinations measured
the best-corrected visual acuity (BCVA), central corneal
thickness (CCT), graded cataract density using a slit lamp,
Goldmann applanation tonometry and corneal endothelial
cell count. The corneal thickness was measured by ultra-
sonic pachymetry using the OcuScan system (Alcon
Laboratories, Inc.). Three acceptable values were generated
for each eye, and a mean value was obtained. Visual acuity
was measured using the Early Treatment of Diabetic
Retinopathy Study charts under photopic conditions (target
luminance of 85 cd/m2).
The same experienced surgeon performed all surgeries
under topical anesthesia. Phacoemulsification was performed
with the Infinity Vision System (Alcon Laboratories, Inc.)
using a standardized surgical technique (stop-and-chop). A
2.4-mm-wide, 2-step corneal incision was fashioned, and a
continuous curvilinear capsulorhexis was made using a
forceps under viscoelastic protection. The lens nucleus and
cortex were hydrodissected with a balanced salt solution.
This dissection was followed by 1-handed irrigation and
aspiration (I/A) to ensure that the cortex was completely
removed. A 3-piece, foldable, acrylic IOL (Alcon Laboratories,
Inc.) was implanted in the capsular bag. The rear section of
the IOL surface was aspirated to completely remove the OVD
under the IOL.
An envelope system was used to randomly assign all
enrolled patients to an OVD regimen. Sequenced and sealed
envelopes containing the first type of OVD (2.0% HPMC or
DisCoVisc) were prepared before surgery. An unscrubbed
observer in the operating room opened the envelopes and
assigned each patient to the prescribed option. The second
eye was treated later and received the other viscoelastic
agent for all steps of the phacoemulsification.
The following components were measured intraopera-
tively: the total volume of the OVD used; cumulative
dissipated energy (CDE), ultrasound time during phacoe-
mulsification and washout time to remove the OVD.
Postoperatively, the patients were administered 0.5%
moxifloxacin four times per day for one week and 0.1%
dexamethasone four times per day for one week and three
times per day for an additional two weeks.
After surgery, each patient was examined at 5, 24 and
48 hours, 7 and 14 days and 3 and 6 months postoperatively.
The corneal endothelial cell count was measured preopera-
tively and at six months postoperatively.
During all examinations, the patient and the observer
were masked concerning the OVD used in each eye.
Statistical analyses were performed using SPSS for
Windows (version 11.5; SPSS, Inc., Chicago, Illinois, USA).
For the primary outcome measures, the statistical tests were
conducted at a level of p,0.05. For the statistical analysis of
visual acuity, the logarithm of the minimal angle of
resolution acuity value was used. The analysis was based
on a non-normal distribution of the data. The two OVDs
were compared between eyes intra-individually. The statis-
tical analyses were performed using the unpaired t-test,
ANOVA, chi-square test, Fisher’s exact test and the Mann-
Whitney U-test.
RESULTS
Seventy-eight eyes from 39 consecutive patients (13 men
[33.3%] and 26 women [66.7%]) were enrolled in the study.
The mean age of the patients was 71.5¡7.9 years. No
significant differences were observed between groups
regarding the mean IOL power (p= 0.597), cataract density
(p= 0.363), preoperative BCVA (p= 0.695) or endothelial cell
count (p= 0.676). No eyes experienced intraoperative or
postoperative complications.
Table 1 lists the intraoperative variables measured. It
took significantly more time to remove the 2.0% HPMC
(0.22¡0.09 min) than the DisCoVisc (0.17¡0.06 min)
(p,0.001), and the amount of viscoelastic material used was
greater with 2.0% HPMC (1.35¡0.20 ml) than DisCoVisc
(0.89¡0.11 ml) (p,0.001). No significant difference was
found between groups regarding the mean ultrasound time
(p= 0.456) or CDE (p= 0.401).
The mean preoperative central corneal thickness was
535.3¡33.9 mm in the DisCoVisc group and 538.2¡35.9 mm
in the 2.0% HPMC group (p= 0.756) (Table 2). The corneas
had increased in thickness at 5 hours after the operation
(p,0.001) but began to decrease by 24 hours, reaching
preoperative levels at three months post-surgery. No
Table 1 - Intraoperative variables.
DisCoVisc 2.0% HPMC p-value
Amount of viscoelastic used (mL)
Mean¡SD 0.89¡0.11 1.35¡0.20
Median 0.9 1.50 0.001*
Range 0.70–1.00 0.75–1.50
CDE
Mean¡SD 17.28¡8.92 15.57¡9.11
Median 16.31 15.41 0.401
Range 4.22–39.06 0.20–42.64
Ultrasound time (min)
Mean¡SD 0.61¡0.38 0.56¡0.45
Median 0.47 0.40 0.456
Range 0.16–1.40 0.10–2.30
Washout time of viscoelastic (min)
Mean¡SD 0.17¡0.06 0.22¡0.09
Median 0.15 0.20 0.001*
Range 0.10–0.36 0.12–0.51
*statistically significant; CDE = cumulative dissipated energy;
HPMC = hydroxypropylmethylcellulose.
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statistically significant difference was found between the
OVDs at any postoperative time point (p= 0.533).
At five hours postoperatively, all groups had increased
IOP (p,0.001), which gradually decreased to the preopera-
tive levels by seven days post-surgery. The highest mean IOP
values were observed in the 2.0% HPMC group (14.4¡3.8
mmHg) at 5 hours postoperatively (p= 0.951). The mean IOP
values obtained at all examinations are shown in Table 2.
There was no statistically significant difference between
OVDs at any examination point (p= 0.834). Only 1 eye (1.2%)
demonstrated an IOP less than 5 mmHg (in the DisCoVisc
group at 24 hours), and no IOP spike greater than 30 mmHg
was measured in either group (Table 2).
There was a statistically significant difference between
OVDs in terms of the postoperative mean BCVA, but only at
24 hours post-surgery (0.35¡0.28 and 0.53¡0.43 logMAR
in the DisCoVisc and 2.0% HPMC groups, respectively
[p,0.0001]). At 6 months, the mean BCVA was 0.02¡0.07
logMAR in the DisCoVisc group and 0.05¡0.10 logMAR in
the 2.0% HPMC group (p= 0.104).
The mean extent of corneal endothelial cell loss at six
months postoperatively was 1.0¡8.6% in the DisCoVisc
group and 3.5¡8.2% in the 2.0% HPMC group (p,0.001).
Table 2 shows the distribution of corneal endothelial cell
counts over time.
DISCUSSION
This contralateral eye study was conducted to analyze the
overall clinical performance of two OVDs during phacoe-
mulsification. The clinical usefulness of DisCoVisc in cataract
surgery has not been reported previously, with the exception
of a few clinical studies that compared DisCoVisc to a soft-
shell technique using 3.0% sodium hyaluronate/4.0% chon-
droitin sulfate (Viscoat) and 1.0% sodium hyaluronate
(Provisc) (11) or to 2.3% sodium hyaluronate (Healon5)
(12,13).
In the present study, we compared DisCoVisc to 2.0%
HPMC in operations where a single surgeon performed all
surgeries using the same standardized technique.
Clinically significant elevations in IOP following unevent-
ful cataract surgery occur in a small percentage of cases.
This IOP increase rarely exceeds 30 mmHg in nonglauco-
matous eyes and is transient in most cases (14-16), which is
in agreement with our results.
We found no significant difference in postoperative IOP
between the use of DisCoVisc and 2.0% HPMC with topical
anesthesia. Five hours postoperatively, all groups had
increased IOP (p,0.001), which gradually decreased to
preoperative levels at 7 days post-surgery. Holzer et al. (17)
analyzed five OVDs and showed that all groups demon-
strated increased IOP at 4 hours postoperatively and that no
significant difference was found between groups. Rainer
et al. (9) observed IOP spikes more often with 2.0% HPMC
than with 1.0% sodium hyaluronate during the 2-hour
postoperative period, whereas in our study, no IOP
exceeded 30 mmHg in any group. The OVDs were removed
with great care from the anterior chamber as well as from
behind the IOL at the end of the surgeries, which may
indicate that both OVDs were effectively and successfully
washed out in our study. Another previous study showed
that 4.0% chondroitin sulfate/3.0% sodium hyaluronate
(dispersive OVD) caused a significantly higher IOP increase
and significantly more IOP spikes than 2.0% HPMC (18).
It is widely assumed that the peak of postoperative IOP
increase occurs 4-7 hours after surgery (19), which is in
agreement with our results. However, these findings are not
in complete agreement with the results of others studies
(9,20). The main reason for the postoperative IOP increase
seems to be the amount of remaining OVD at the end of the
cataract surgery.
We observed an increase in CCT after phacoemulsifica-
tion in both groups. Following this increase, the CCT
decreased continuously in both groups, reaching preopera-
tive levels at three months post-surgery. The absolute
difference in CCT did not vary significantly between the
groups preoperatively or at any time postoperatively, which
may be attributed to the fact that the OVDs used in both
groups have dispersive properties and because this study
was conducted in patients with simple age-related cataracts
with no other ocular complications.
Praveen et al. (11) performed a study to evaluate the safety
and efficacy of DisCoVisc and found no significant difference
in CCT measurements preoperatively and at seven days or
one month postoperatively compared to the use of 3.0%
sodium hyaluronate/4.0% chondroitin sulfate and 1.0%
sodium hyaluronate. Davis et al. (6) also found no difference
in postoperative CCT measurements when comparing 1.6%
sodium hyaluronate (Amvisc Plus), 4.0% chondroitin sul-
fate/3.0% sodium hyaluronate and 2.0% HPMC.
The ability of OVDs to remain in the eye and their ease of
removal are important issues during cataract surgery (10).
As shown in the present study, the removal time of the OVD
was significantly shorter with DisCoVisc. In addition, the
results of previous studies have demonstrated that the
removal time of DisCoVisc was shorter than that of 2.3%
sodium hyaluronate (11) but longer than that of 1.0%
sodium hyaluronate in porcine eyes (21). The study by
Bissen-Miyajima et al. (10) further analyzed the in vitro
Table 2 - Primary outcome variables (DisCoVisc versus
HPMC 2.0%).
Variables
DisCoVisc
Mean¡SD
2.0% HPMC
Mean¡SD p-value
Corneal Thickness (mm)
Preoperative 535.3¡33.9 538.2¡35.9 0.756
Postoperative
5 hours 620.7¡72.6 628.4¡59.2 0.634
24 hours 605.5¡74.8 605.9¡58.1 0.896
48 hours 583.7¡51.3 588.2¡49.6 0.698
7 days 574.5¡57.8 572.4¡46.9 0.860
14 days 558.9¡38.5 560.2¡45.6 0.897
3 months 543.2¡36.8 543.8¡39.5 0.943
6 months 538.6¡36.0 541.3¡36.6 0.744
Intraocular Pressure (mmHg)
Preoperative 13.4¡2.3 13.5¡2.1 0.756
Postoperative
5 hours 14.3¡3.6 14.4¡3.8 0.951
24 hours 13.5¡3.9 14.3¡3.6 0.325
48 hours 13.1¡3.0 12.9¡2.8 0.813
7 days 12.9¡2.4 13.1¡3.9 0.780
14 days 13.0¡3.1 12.6¡3.3 0.645
3 months 12.6¡2.2 12.6¡2.3 0.880
6 months 12.2¡1.8 12.5¡2.3 0.510
Endothelial cell count (cells/mm2)
Preoperative 2,358¡334 2,364¡358 0.758
Postoperative
6 months 2,214¡372 2,032¡460 0.001*
N statistically significant; HPMC = hydroxypropylmethylcellulose.
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behavior of OVDs and showed that the removal time for
DisCoVisc was between those of cohesive (1.0% sodium
hyaluronate) and dispersive (3.0% sodium hyaluronate/
4.0% chondroitin sulfate) OVDs.
The current study found that corneal endothelial cell loss
was significantly lower in the DisCoVisc group, which was
most likely due to its superior retention compared to 2.0%
HPMC during phacoemulsification. The study by Oshika
et al. (12) also demonstrated better endothelium protection
with DisCoVisc.
Considering the amount of viscoelastic material used
during phacoemulsification, a significantly larger quantity
of 2.0% HPMC was needed to perform all steps of the
surgery, which implies that DisCoVisc was a more efficient
OVD. In addition, Praveen et al. (11) found that a single
injection of DisCoVisc was a safe and effective alternative to
the use of multiple OVDs.
Our study did not include eyes with dense sclerosis, as
dense cataract emulsification is cited as a risk factor for
excessive cell loss (22,23). Furthermore, there were no
statistically differences between the two OVD groups in
terms of cataract density, ultrasound time or CDE (Table 1),
thus eliminating any potential effects of these variables. The
fact that this study utilized a contralateral comparison
minimized intra-individual factors that could have inter-
fered with the outcomes.
However, one limitation of this study was that only
simple cataract cases were included. One previous study
(24) evaluating DisCoVisc in complex ocular environments
showed that this OVD facilitated good intraoperative
performance in complex cases and was effective in simple
cataract surgeries; however, this study was observational
and non-comparative.
In conclusion, the viscous, dispersive OVD DisCoVisc
was more efficient during phacoemulsification and was
able to be more rapidly removed after IOL implantation
compared to 2.0% HPMC. The degree of corneal endothelial
cell loss was also significantly lower with DisCoVisc than
with 2.0% HPMC, which promoted improved corneal
endothelium protection at 6 months postoperatively.
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